FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site

Scholar Rock received a Complete Response Letter (CRL) from the FDA for its spinal muscular atrophy (SMA) drug apitegromab due to manufacturing issues at a third-party contract facility (Catalent Indiana, now owned by Novo Nordisk), explicitly stating no concerns regarding the drug's efficacy or safety. This facility has a history of FDA compliance problems, previously impacting Regeneron's product approvals, highlighting broader systemic issues. While delaying Scholar Rock's first potential market entry for a drug with projected $1.8 billion peak sales and significant potential in muscle preservation for SMA and obesity treatment, the company plans to resubmit its application once the operational hurdles are resolved, positioning this as a temporary setback for a high-potential asset.

Analysis

Scholar Rock (SRRK) has received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for apitegromab, a potential first-in-class muscle-targeted treatment for spinal muscular atrophy (SMA). The rejection is not based on any clinical concerns regarding the drug's safety or efficacy, but rather on manufacturing issues at a third-party facility in Indiana, now owned by Novo Nordisk (NVO) following its acquisition of Catalent. This specific facility has a documented history of compliance problems, having previously caused approval delays for Regeneron's (REGN) high-dose Eylea and odronextamab, indicating a systemic operational risk at the site rather than a failure specific to Scholar Rock. While this CRL delays Scholar Rock's transition to a commercial-stage company, its financial position appears stable with a cash runway into 2027. The fundamental value proposition of apitegromab remains strong, supported by analyst peak sales projections of $1.8 billion and its significant potential as a combination therapy to mitigate muscle loss in the obesity drug market. The company had previously warned of this potential outcome, and it plans to resubmit the BLA once the manufacturing partner resolves the FDA's observations.

Key Decisions for Investors

• Investors should monitor communications from Scholar Rock and Novo Nordisk regarding the remediation timeline at the Bloomington manufacturing facility, as this is the primary catalyst for the BLA resubmission and subsequent approval.
• Given the CRL is due to an operational issue, not a clinical failure, any significant stock price weakness in Scholar Rock could represent a long-term entry point, as the drug's intrinsic value and $1.8 billion peak sales potential remain intact.
• Evaluate exposure to other biotech companies reliant on the ex-Catalent Bloomington facility, as its recurring FDA compliance issues pose a systemic risk to product launch timelines that extends beyond Scholar Rock and has already impacted Regeneron.